LAKEWOOD, Colo. – February 14, 2023 – Terumo Blood and Cell Technologies today announced that its IMUGARD™ Platelet Pooling Set has received clearance from the U.S. FDA, expanding options for blood centers preparing pooled platelet products.
The IMUGARD Platelet Pooling Set is designed to support the preparation of pooled platelet concentrates, providing blood centers with a reliable, standardized solution for platelet processing to help meet patient transfusion needs.
"This FDA clearance allows us to offer blood centers an important new tool for platelet pooling," said a Terumo Blood and Cell Technologies representative. "We remain committed to providing solutions that support the availability of safe, high-quality blood products for patients."
The IMUGARD Platelet Pooling Set adds to Terumo Blood and Cell Technologies' broader portfolio of blood processing solutions available to blood centers in the United States.
About Terumo Blood and Cell Technologies
Terumo Blood and Cell Technologies, a Terumo group company, is a global leader committed to providing high-quality products and services for blood and blood component collection, and for the production of biotherapies, including cell and gene therapies. Together with our partners and customers, we envision and advance a world where blood and cell technologies contribute to the health and well-being of all people.
